Entering text into the input field will update the search result below

Data from Revlimid study published in New England Journal of Medicine

Aug. 01, 2013 10:22 AM ETCelgene Corporation (CELG) StockCELGBy: Colin Lokey, SA News Editor
  • Data from a Phase II study of a Revlimid/ dexamethasone combo followed by Revlimid (CELG +1.6%) maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma have been published in the August 1 edition of the New England Journal of Medicine.
  • Primary endpoint results: At a median follow-up of 40 months, median time to progression was "significantly longer in the treatment group compared with the observation group." (PR, full article)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
CELG--
Celgene Corporation